Liver Disease
News from the FDA/CDC
FDA Approves First Drug for MASH
Resmetirom is a once-daily, oral thyroid hormone receptor beta-selective agonist.
Latest News
Semaglutide Curbs MASLD Severity in People Living With HIV
Most participants lost significant weight and weight loss was closely associated with improvements in MASLD.
From the Journals
Seladelpar Could ‘Raise the Bar’ in Primary Biliary Cholangitis Treatment
Improvements on the 5-D Itch Scale in both the moderate to severe pruritus population and the overall population also favored seladelpar over...
From the Journals
NEJM Study Highlights Resmetirom’s Efficacy in NASH With Liver Fibrosis
Although to date the MAESTRO-NASH trial lacks clinical outcomes, over its planned duration of 54 months, investigators will accrue data on liver-...
From the AGA Journals
Meta-Analysis Highlights Litany of MASLD-Associated Complications, Encouraging New Treatment Targets
The findings emphasize the multisystemic nature of MASLD, suggesting that broader treatment targets are needed.
From the AGA Journals
Dueling Gut Bacteria Impact Chronic HBV Progression
These findings could lead to new therapeutic strategies, researchers say.
Pearls from the Pros
Iron Overload in Non-HFE Liver Disease: Not all Iron is Ready to Strike
In any patient with chronic liver disease, an elevated serum ferritin or an elevated iron saturation should prompt testing for HFE mutations to...
From the Journals
New Guideline Offers Recommendations for Alcohol-Associated Liver Disease
The guidelines note the importance of policy aimed at alcohol use reduction, multidisciplinary care for alcohol use disorder and alcohol-...
Commentary
The Breakthrough Drug Whose Full Promise Remains Unrealized
With its approval in 2013, sofosbuvir revolutionized the treatment of hepatitis C, but the goal of eliminating this disease is still decades away...
The New Gastroenterologist
February 2024 – ICYMI